← All companies & organizations

Science / Company profile

Chai Discovery

What Chai Discovery does

Chai Discovery is an AI-for-science company building multimodal foundation models and a computer-aided design (CAD) workflow for molecular and protein (especially antibody) engineering. The company positions its platform as a “design suite” that helps teams move from specifying target criteria toward generating de novo biomolecular candidates, with emphasis on reliable design (including full mAb formats), controllable properties (e.g., epitope targeting, agonism vs antagonism), and faster experimental iteration cycles. Chai’s models are deployed with pharmaceutical partners via licensing/collaboration agreements, and access is also offered for commercial and academic use through an online request workflow.

News

Company record

Aug 20, 2026 · Official · Chai Discovery (Business Wire reprint)Chai Discovery Announces Collaboration with Bristol Myers Squibb to Advance AI-Driven Antibody Discovery

Bristol Myers Squibb will leverage Chai’s AI models and platform capabilities to support antibody candidate discovery across BMS’s portfolio and build an AI-powered continuously learning discovery system.

↗
Jul 15, 2026 · Official · Chai Discovery (Business Wire reprint)Chai Discovery Enters Into Collaboration Agreement With argenx to Advance AI-Driven Immunology Breakthroughs

argenx will gain early access to Chai’s AI platform to support de novo antibody discovery across therapeutic targets; Chai also describes Chai-2 and mentions Chai-3 as its latest model improving performance across binding and design-related factors.

↗
Jul 14, 2026 · Official · Chai DiscoveryChai Discovery Announces $400M Series C to Advance AI-Driven Molecular Design

Chai announced a $400M Series C at a $3.8B valuation, naming Index Ventures, Kleiner Perkins, Sequoia Capital, Dimension, and others, and describing goals around accelerating compute/data and product development.

↗
Jul 13, 2026 · Official · Chai Discovery (news index entry)Chai Discovery Announces Collaboration with Novartis to Advance AI-Driven Antibody Discovery

Novartis will gain access to Chai Discovery’s AI design models and platform to support therapeutic antibody discovery across multiple targets.

↗
Nov 19, 2025 · Official · Chai Discovery (research update)Drug-like antibody design against challenging targets with atomic precision

Chai reports that Chai-2 can design full-length, drug-like mAbs while maintaining high hit rates, presents results on developability criteria for a set of designed antibodies, and describes Cryo-EM validation of designed antibody-antigen complexes at sub-angstrom scale.

↗
Jun 30, 2025 · Official · Chai Discovery (Series A announcement referencing Chai-2 breakthrough)Chai Discovery Unveils Chai-2 Breakthrough, Achieving Fully De Novo Antibody Design With AI

Chai describes Chai-2 as delivering fully de novo antibody design with a near-20% hit rate, contrasting it with traditional lab-based screening and prior computational approaches; it is referenced in the Series A announcement and listed in the news index.

↗
Sep 09, 2024 · Official · Chai DiscoverySeed: Announcing our first fundraise

Chai Discovery announced raising ~$30M in a Seed round led by Thrive Capital, OpenAI, and Dimension Capital, and described releasing Chai-1 as a foundation model for molecular structure prediction.

↗
Source map · 2 recurring channels · 68 references
Chai DiscoveryOfficial Site · monitor↗MTS Frontier / Control RoomCurated Feed · monitor↗lab.chaidiscovery.comOfficial Reference · reference↗Official company sourceOfficial Reference · reference↗aiwiki.aiReporting · reference↗app.dealroom.coReporting · reference↗arias-us.orgReporting · reference↗arxiv.orgReporting · reference↗attachment.news.eu.nasdaq.comReporting · reference↗axios.comReporting · reference↗biobase.whitefordresearch.comReporting · reference↗bioutah.orgReporting · reference↗ca.finance.yahoo.comReporting · reference↗caplight.comReporting · reference↗carlsquare.comReporting · reference↗cbinsights.comReporting · reference↗chai-research.comReporting · reference↗chai.orgReporting · reference↗chaiassets.comReporting · reference↗chambers.comReporting · reference↗crunchbase.comReporting · reference↗discoveryworld.orgReporting · reference↗employbl.comReporting · reference↗en.wikipedia.orgReporting · reference↗fenwick.comReporting · reference↗files-backend.assets.thrillshare.comReporting · reference↗forbes.comReporting · reference↗forgeglobal.comReporting · reference↗generalcatalyst.comReporting · reference↗giievent.twReporting · reference↗gire.mashreqdevelopments.comReporting · reference↗higherlogicdownload.s3.amazonaws.comReporting · reference↗hinsdale.churchReporting · reference↗indexventures.comReporting · reference↗info.crosstreecapital.comReporting · reference↗intro-act.comReporting · reference↗intuitionlabs.aiReporting · reference↗journal-quarum.comReporting · reference↗kfc.upol.czReporting · reference↗komo.aiReporting · reference↗linkedin.comReporting · reference↗megadeal.blogReporting · reference↗menlovc.comReporting · reference↗mobile.twstalker.comReporting · reference↗neo.substack.comReporting · reference↗nyalliance.starchapter.comReporting · reference↗pitchbook.brightspotcdn.comReporting · reference↗reddit.comReporting · reference↗research.contrary.comReporting · reference↗rothschildandco.comReporting · reference↗s3.amazonaws.comReporting · reference↗seedtable.comReporting · reference↗sib.wa.govReporting · reference↗siliconvalleyinvestclub.comReporting · reference↗site.twstalker.comReporting · reference↗startup-index.comReporting · reference↗static.seekingalpha.comReporting · reference↗static1.squarespace.comReporting · reference↗static2.finnhub.ioReporting · reference↗stockanalysis.comReporting · reference↗talentoptimizers.comReporting · reference↗techcrunch.comReporting · reference↗theailandscape.comReporting · reference↗thecenterfordiscovery.orgReporting · reference↗theofficialboard.comReporting · reference↗theofficialboard.deReporting · reference↗theofficialboard.esReporting · reference↗trueup.ioReporting · reference↗ttifloorcare.mashreqdevelopments.comReporting · reference↗youtube.comReporting · reference↗

Still resolving: Newsroom · Official X

Funding

Latest disclosed valuationNot disclosed
Tracked capital$100M2 sourced rounds

What it builds

Chai-2 (de novo protein design models)

Chai’s de novo protein design product is presented as a model series that supports antibody format specification (including mAbs and VHH/VH-VL), prompt-based targeting (public/private structures or predicted structure inputs), epitope-specific design (including small/buried/non-immunogenic epitopes), handling of chemical modifications such as PTMs and glycans, and explicit design criteria such as controlling species/ortholog specificity or cross-reactivity; the company states it is opening up access to commercial organizations.

source ↗
Chai-3 (frontier model mentioned in Series C update)

In its Series C announcement, Chai says its latest model, Chai-3, is unlocking previously difficult targets and improving performance across areas relevant to therapeutic binding and design workflows.

source ↗
Chai-1 (foundation model for molecular structure prediction)

In its Seed announcement, Chai describes releasing Chai-1 as a foundation model for molecular structure prediction intended to perform at state-of-the-art across tasks relevant to drug discovery.

source ↗

Key metrics

Milestones & partnerships